Skip to content
Boston Pharmaceutical Support
  • Home
  • Business
    • Boston Market Review
    • Business Development Portal
    • CRO & CDMO Reports
    • CRM Portal
  • Science
    • Process Technology Portfolio
  • Quality
    • Pharmaceutical Quality/CMC – Guidances
    • CMC Development Strategies for Small Pharma
    • The Role of CMC In Early Trials
  • Clients
  • Contact
Boston Pharmaceutical Support

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector

Shares of Alexion Pharmaceuticals Inc. (ALXN) rose 6.7% to $139.88 in premarket trading on Thursday, July 27, after the New Haven, Conn.-based firm unveiled second-quarter results.

Source: Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers – TheStreet

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

Related

Post navigation

Tetraphase Claws Back From Failed Study, Eyes FDA Filing With New Data
Shire Stock Rising on Takeover Talks – TheStreet
© Boston Pharmaceutical Support 2016 • © Boston Baseline Digital Marketing 2017 • BPS Black Ops Team •